Navigation Links
ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
Date:3/18/2011

as designated an orphan medicinal product on October 8, 2009. Upon granting of a Centralized Marketing Authorization and retention of the orphan medicinal product designation, Cinryze would be entitled to a period of 10 years market exclusivity in respect of the approved therapeutic indication. This 10-year market exclusivity period could be extended cumulatively to 12 years when the results of all studies conducted in compliance with an agreed pediatric investigation plan are completed and included in the summary of product characteristics.

About Cinryze® (C1 esterase inhibitor [human])

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product.  In the U.S., Cinryze was approved by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.  In the E.U., the recommended indication is for treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE), and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments or patients who are inadequately managed with repeated acute treatment.

Severe hypersensitivity reactions to Cinryze may occur.  Thrombotic events have occurred in patients receiving Cinryze for routine prophylaxis, and in patients receiving off-label high dose C1 inhibitor therapy.  Monitor patients with known risk factors for thrombotic events.  With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening donors for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.  <
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015 Releases ... ,Friendly Aedes aegypti , , reduced the ... Brazil by 95%, well below the ... (Logo: http://photos.prnewswire.com/prnh/20150630/227348LOGO) , The journal PLOS Neglected ... of Oxitec,s genetically engineered mosquitoes. The results showed that ...
(Date:7/2/2015)...   EVO Aesthetic Center and Wellness Spa ... aesthetics in Lakeway, Texas and ... Astanza Duality laser. The medical spa is focused on ... and laser procedures. Their addition of the Astanza Duality ... to their tattoo regret. "The large number ...
(Date:7/2/2015)... N.C. , July 2, 2015 ... assets related to the ion channel biology platform from ... been obtained as part of Pfizer,s 2011 acquisition of ... rights to the "Icagen" name and trademark.  XRPro Sciences ... services for ion channel and transporter drug discovery, combining ...
Breaking Medicine Technology:Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4
... BOULDER, Colo. , July 28 Encision Inc. (OTC ... is emerging as a standard of care in minimally-invasive surgery, recognized as ... , , ... 3rd International Laparoscopic Complication meeting, May 14, 2010 by ...
... July 28 Oxford Finance Corporation, a subsidiary ... lead lender for a $30 million credit ... GE Financial Services, Inc. also participated in the loan ... potential launch of their investigational product candidate, OFIRMEV™, an ...
Cached Medicine Technology:Encision's Technology Recognized as A Means to Eliminate Surgery Burns 2Encision's Technology Recognized as A Means to Eliminate Surgery Burns 3Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals 2
(Date:7/3/2015)... Greenville, SC (PRWEB) , ... ... ... Society has announced the sessions and speaker lineup for its 2015 ... nursing, taking place August 6-8, 2015 at the Renaissance Orlando at SeaWorld ...
(Date:7/3/2015)... ... July 03, 2015 , ... Scientists at several top US cancer centers ... minimal asbestos exposure. Click here to read the complete story , just posted ... Center, Cedars Sinai Medical Center, and New York University exposed mice with a mutation ...
(Date:7/3/2015)... ... ... Renowned rhinoplasty surgeon and Symposium Chairman, Dr. Rod J. Rohrich , ... held from March 4th - 6th, the 2016 (a previous announcement had stated the ... to take participants from the basic training and fundamentals of nasal surgery through the ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. Smith, the ... to lead a national president recruitment for Regional Care, Inc. in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... ... exclusively to healthcare providers, has been retained to lead a national chief ... of the top-ranked executive search firms in the healthcare industry, B. E. Smith ...
Breaking Medicine News(10 mins):Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... ... the emerging medical travel space, announced that international medical quality authority, Dr. David Jaimovich, ... ... Satori World Medical, a leading global healthcare company specializing in the emerging medical travel ...
... smoke are at risk of lung cancer , THURSDAY, Dec. ... of malignancies caused by smoking, with a new study strengthening ... providing more bad news for people who haven,t managed to ... Epidemiology, Biomarkers & Prevention , a themed issue on tobacco, ...
... , Diabetes: A ... Hands-on Experience for All Ages , DETROIT, Dec. 3 ... seconds. On December 5, 2009, the Detroit Science Center will debut its ... that the public might have about diabetes, diabetes treatment and the role ...
... , HOUSTON, Dec. 3 Three US Oncology, Inc ... the Occupational Safety & Health category from the National ... Specialty, LP ; US Oncology Clinical & Research Pharmacy distribution ... have continuously received the Occupational Excellence Award from the national ...
... protected volunteers from virus linked to cervical cancer , WEDNESDAY, ... Cervarix protects women from infection for longer than six years, ... two types of HPV (HPV-16 and HPV-18) most commonly associated ... women, aged 15 to 25, with a normal cervical profile ...
... , Unfair Labor Practices, Protecting Donors, and ... Teamsters who work at American Red Cross (ARC) Blood ... protest unfair labor practices and problems with working conditions at ... the integrity of the blood supply, not to mention the ...
Cached Medicine News:Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 2Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 3Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 4Health News:Smoking Exposure Now Linked to Colon, Breast Cancers 2Health News:Smoking Exposure Now Linked to Colon, Breast Cancers 3Health News:Smoking Exposure Now Linked to Colon, Breast Cancers 4Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 2Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 3Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 4Health News:US Oncology Celebrates Consecutive Safety 2Health News:US Oncology Celebrates Consecutive Safety 3Health News:Cervarix Proves Effective Against HPV for Over 6 Years 2Health News:Philadelphia Red Cross Blood Workers Strike to Protect Donor and Blood Safety 2
... million people are diagnosed with varicose veins ... patients never seek treament and are apprehensive ... offer them an effective alternative to conventional ... or hook phlebectomy), is considered a laborious ...
...
Inquire...
Inquire...
Medicine Products: